Related Experiment Video
Updated: May 21, 2025
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
Clinical benefits of evolocumab in diabetic patients with STEMI undergoing PCI: a retrospective study
1Cardiovascular Department, The Second Hospital of Hebei Medical University Shijiazhuang 050000, Hebei, P. R. China.
Insights
Evolocumab significantly benefits diabetic patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI). This treatment reduced cardiovascular events and improved lipid levels without increasing adverse reactions.
Area of Science:
- Cardiology
- Pharmacology
- Diabetology
Background:
- Diabetic patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI) often face higher risks.
- The clinical benefit of evolocumab in this specific high-risk population in China was previously unclear.
Purpose of the Study:
- To assess the safety and efficacy of evolocumab in Chinese diabetic patients with STEMI undergoing PCI.
- To evaluate evolocumab's impact on blood lipid levels, LVEF, and adverse events.
Main Methods:
- A retrospective study of 184 diabetic patients with STEMI undergoing PCI.
- Patients were divided into evolocumab and control groups.
- Evaluated primary efficacy endpoint, blood lipids, and adverse events at 6 and 12 months.
Main Results:
- Evolocumab significantly reduced blood lipid levels and intima-media thickness, while increasing LVEF.
- A significant reduction in the primary efficacy endpoint was observed in the evolocumab group.
- No significant difference in adverse reactions between groups; prognostic model identified evolocumab as protective.
Conclusions:
- Evolocumab demonstrates significant clinical benefits for diabetic patients with STEMI undergoing PCI.
- Findings support considering evolocumab to mitigate future cardiovascular event risk in this patient cohort.
Objective:
It was unclear whether the clinical benefit of evolocumab extended to diabetic patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI) in China. In this study, the safety and efficacy of evolocumab in treating diabetic patients with STEMI undergoing PCI was assessed.
Methods:
A retrospective study was conducted involving 184 diabetic patients with STEMI PCI. The patients were assigned to either the evolocumab group or the control (Ctrl) group based on whether they were treated with evolocumab. After six months of treatment and 12 months of follow-up, the primary efficacy endpoint, blood lipid levels, and adverse events were evaluated. Additionally, a prognostic model was developed to examine the relationship between evolocumab intervention and primary efficacy endpoint.
Results:
Blood lipid levels and intima-media thickness decreased significantly and the LVEF levels increased significantly in patients after treatment with evolocumab compared to those in patients after administering a standard therapy. Treatment with evolocumab also led to a significant reduction in the primary efficacy endpoint. Moreover, no difference in the incidence of adverse reactions was recorded between the groups. The prognostic model constructed showed that evolocumab intervention was a protective factor for the primary efficacy endpoint.
Conclusions:
Administering evolocumab had greater benefits for diabetic patients with STEMI undergoing PCI. Our findings might encourage doctors to consider use evolocumab to reduce the risk of future cardiovascular events in diabetic patients with STEMI.
More Related Videos
18:11A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
Published on: December 28, 2012
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
Related Concept Videos
01:17Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
01:16Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...